AC IMMUNE SA
AC IMMUNE SA
Share · CH0329023102 · ACIU · A2AR5F (XNAS)
Overview Financial Indicators
2,15 USD
-1,83 % -0,04 USD
NASDAQ (XNAS) · Current prices and charts at MoneyPeak
11.06.2025 20:58

Current Prices from AC IMMUNE SA

ExchangeTickerCurrencyLast TradePriceDaily Change
XNAS: NASDAQ
NASDAQ
ACIU
USD
11.06.2025 20:58
2,15 USD
2,19 USD
-1,83 %

Performance

Day Week Month 3 Months 6 Months 1 Year 5 Years
0,00 % 26,47 % 27,98 % -4,44 % -31,09 % -52,01 % -68,15 %

Company Profile for AC IMMUNE SA Share

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

Invested Funds

The following funds have invested in: AC IMMUNE SA invested:

Fund
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Vol. in million
17,87
Percentage (%)
0,04 %

Company Data

Name AC IMMUNE SA
Company AC Immune SA
Symbol ACIU
Website https://www.acimmune.com
Primary Exchange XNAS NASDAQ
WKN A2AR5F
ISIN CH0329023102
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Dr. Andrea Pfeifer Ph.D.
Market Capitalization 147 Mio
Country Switzerland
Currency USD
Employees 0,1 T
Address Building B, 1015 Lausanne
IPO Date 2016-09-23

Ticker Symbols

Name Symbol
Frankfurt IMR.F
NASDAQ ACIU

More Shares

Investors who AC IMMUNE SA hold also have the following shares in their portfolio:
CD PROJEKT SA
CD PROJEKT SA Share
COVESTRO AG
COVESTRO AG Share
CROPENERGIES AG
CROPENERGIES AG Share
ISHS IV-AUTO.+ROBO.ET.DLD
ISHS IV-AUTO.+ROBO.ET.DLD ETF
POWERTAP HYDRO.CAP.CORP
POWERTAP HYDRO.CAP.CORP Share
S&P 500 UCITS ETF - (USD) DISTRIBUTING
S&P 500 UCITS ETF - (USD) DISTRIBUTING ETF
TURK.SI.KAL.BK 17/27 FLR
TURK.SI.KAL.BK 17/27 FLR Bond
VNET GROUP 22/26 ZO CV
VNET GROUP 22/26 ZO CV Bond
VODAFONE
VODAFONE Share
WALT DISNEY INC
WALT DISNEY INC Share
WARNER BROS. DISCOVERY INC
WARNER BROS. DISCOVERY INC Share
WITR MU.AS.I.GAS ETP 2062
WITR MU.AS.I.GAS ETP 2062 ETC
The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Imprint Data Protection Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025